Literature DB >> 25573592

Functional variants of lipid level modifier MLXIPL, GCKR, GALNT2, CILP2, ANGPTL3 and TRIB1 genes in healthy Roma and Hungarian populations.

Katalin Sumegi1, Luca Jaromi, Lili Magyari, Erzsebet Kovesdi, Balazs Duga, Renata Szalai, Anita Maasz, Petra Matyas, Ingrid Janicsek, Bela Melegh.   

Abstract

The role of triglyceride metabolism in different diseases, such as cardiovascular or cerebrovascular diseases is still under extensive investigations. In genome-wide studies several polymorphisms have been reported, which are highly associated with plasma lipid level changes. Our goal was to examine eight variants: rs12130333 at the ANGPTL3, rs16996148 at the CILP2, rs17321515 at the TRIB1, rs17145738 and rs3812316 of the MLXIPL, rs4846914 at GALNT2, rs1260326 and rs780094 residing at the GCKR loci. A total of 399 Roma (Gypsy) and 404 Hungarian population samples were genotyped using PCR-RFLP method. Significant differences were found between Roma and Hungarian population samples in both MLXIPL variants (C allele frequency of rs17145738: 94.1% vs. 85.6%, C allele frequency of rs3812316: 94.2% vs. 86.8% in Romas vs. in Hungarians, p < 0.05), in ANGPTL3 (T allele frequency of rs1213033: 12.2% vs. 18.5% in Romas vs. Hungarians, p < 0.05) and GALNT2 (G allele frequency of rs4846914: 46.6% vs. 54.5% Romas vs. in Hungarians, p < 0.05), while no differences over SNPs could be verified and the known minor alleles showed no correlation with triglyceride levels in any population samples. The current study revealed fundamental differences of known triglyceride modifying SNPs in Roma population. Failure of finding evidence for affected triglyceride metabolism shows that these susceptibility genes are much less effective compared for example to the apolipoprotein A5 gene.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25573592     DOI: 10.1007/s12253-014-9884-5

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  49 in total

1.  Approach to lipoprotein management in 2001 National Cholesterol Guidelines.

Authors:  Scott M Grundy
Journal:  Am J Cardiol       Date:  2002-10-17       Impact factor: 2.778

Review 2.  Allelic and phenotypic spectrum of plasma triglycerides.

Authors:  Christopher T Johansen; Robert A Hegele
Journal:  Biochim Biophys Acta       Date:  2011-10-12

3.  Variant in the glucokinase regulatory protein (GCKR) gene is associated with fatty liver in obese children and adolescents.

Authors:  Nicola Santoro; Clarence K Zhang; Hongyu Zhao; Andrew J Pakstis; Grace Kim; Romy Kursawe; Daniel J Dykas; Allen E Bale; Cosimo Giannini; Bridget Pierpont; Melissa M Shaw; Leif Groop; Sonia Caprio
Journal:  Hepatology       Date:  2011-12-18       Impact factor: 17.425

4.  Triglyceride level-influencing functional variants of the ANGPTL3, CILP2, and TRIB1 loci in ischemic stroke.

Authors:  Luca Járomi; Veronika Csöngei; Noémi Polgár; Gábor Rappai; Zoltán Szolnoki; Anita Maász; Katalin Horvatovich; Eniko Sáfrány; Csilla Sipeky; Lili Magyari; Béla Melegh
Journal:  Neuromolecular Med       Date:  2011-06-21       Impact factor: 3.843

5.  Impact of variants within seven candidate genes on statin treatment efficacy.

Authors:  M Vrablík; J A Hubáček; D Dlouhá; V Lánská; J Rynekrová; L Zlatohlávek; M Prusíková; R Ceška; V Adámková
Journal:  Physiol Res       Date:  2012-10-25       Impact factor: 1.881

6.  Apolipoprotein A5 IVS3+476A allelic variant associates with increased trigliceride levels and confers risk for development of metabolic syndrome in Hungarians.

Authors:  Péter Kisfali; Márton Mohás; Anita Maasz; Ferenc Hadarits; Lajos Markó; Katalin Horvatovich; Tamás Oroszlán; Zoltán Bagosi; Zoltán Bujtor; Beáta Gasztonyi; István Wittmann; Béla Melegh
Journal:  Circ J       Date:  2008-01       Impact factor: 2.993

7.  Functional variants of glucokinase regulatory protein and apolipoprotein A5 genes in ischemic stroke.

Authors:  Luca Járomi; Veronika Csöngei; Noémi Polgár; Zoltán Szolnoki; Anita Maász; Katalin Horvatovich; Bernadett Faragó; Csilla Sipeky; Eniko Sáfrány; Lili Magyari; Péter Kisfali; Márton Mohás; Ingrid Janicsek; Lilla Lakner; Béla Melegh
Journal:  J Mol Neurosci       Date:  2009-10-22       Impact factor: 3.444

8.  Polymorphism in the promoter region of the apolipoprotein A5 gene is associated with an increased susceptibility for coronary artery disease.

Authors:  Csaba Szalai; Márton Keszei; Jenõ Duba; Zoltán Prohászka; Gergely Tibor Kozma; Albert Császár; Sándor Balogh; Zsuzsa Almássy; George Fust; Antal Czinner
Journal:  Atherosclerosis       Date:  2004-03       Impact factor: 5.162

9.  Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans.

Authors:  Sekar Kathiresan; Olle Melander; Candace Guiducci; Aarti Surti; Noël P Burtt; Mark J Rieder; Gregory M Cooper; Charlotta Roos; Benjamin F Voight; Aki S Havulinna; Björn Wahlstrand; Thomas Hedner; Dolores Corella; E Shyong Tai; Jose M Ordovas; Göran Berglund; Erkki Vartiainen; Pekka Jousilahti; Bo Hedblad; Marja-Riitta Taskinen; Christopher Newton-Cheh; Veikko Salomaa; Leena Peltonen; Leif Groop; David M Altshuler; Marju Orho-Melander
Journal:  Nat Genet       Date:  2008-01-13       Impact factor: 38.330

10.  Newly identified loci that influence lipid concentrations and risk of coronary artery disease.

Authors:  Cristen J Willer; Serena Sanna; Anne U Jackson; Angelo Scuteri; Lori L Bonnycastle; Robert Clarke; Simon C Heath; Nicholas J Timpson; Samer S Najjar; Heather M Stringham; James Strait; William L Duren; Andrea Maschio; Fabio Busonero; Antonella Mulas; Giuseppe Albai; Amy J Swift; Mario A Morken; Narisu Narisu; Derrick Bennett; Sarah Parish; Haiqing Shen; Pilar Galan; Pierre Meneton; Serge Hercberg; Diana Zelenika; Wei-Min Chen; Yun Li; Laura J Scott; Paul A Scheet; Jouko Sundvall; Richard M Watanabe; Ramaiah Nagaraja; Shah Ebrahim; Debbie A Lawlor; Yoav Ben-Shlomo; George Davey-Smith; Alan R Shuldiner; Rory Collins; Richard N Bergman; Manuela Uda; Jaakko Tuomilehto; Antonio Cao; Francis S Collins; Edward Lakatta; G Mark Lathrop; Michael Boehnke; David Schlessinger; Karen L Mohlke; Gonçalo R Abecasis
Journal:  Nat Genet       Date:  2008-01-13       Impact factor: 38.330

View more
  7 in total

Review 1.  ANGPLT3 in cardio-metabolic disorders.

Authors:  Xin Su
Journal:  Mol Biol Rep       Date:  2021-03-06       Impact factor: 2.316

2.  GALNT2 Gene Variant rs4846914 Is Associated with Insulin and Insulin Resistance Depending on BMI in PCOS Patients: a Case-Control Study.

Authors:  Jinxin Chen; Linbo Guan; Hongwei Liu; Qingqing Liu; Ping Fan; Huai Bai
Journal:  Reprod Sci       Date:  2020-11-10       Impact factor: 3.060

3.  Distinct Penetrance of Obesity-Associated Susceptibility Alleles in the Hungarian General and Roma Populations.

Authors:  Károly Nagy; Szilvia Fiatal; János Sándor; Róza Ádány
Journal:  Obes Facts       Date:  2017-10-07       Impact factor: 3.942

4.  Association study of genetic variants of the ANGPTL3 gene and susceptibility to ischemic stroke.

Authors:  Qi Gong; Liping Ye; Huiwen Gui; Jing Liu; Huanyin Li; Qian Sun
Journal:  Neuropsychiatr Dis Treat       Date:  2019-10-24       Impact factor: 2.570

5.  Association of the variants and haplotypes in the DOCK7, PCSK9 and GALNT2 genes and the risk of hyperlipidaemia.

Authors:  Tao Guo; Rui-Xing Yin; Wei-Xiong Lin; Wei Wang; Feng Huang; Shang-Ling Pan
Journal:  J Cell Mol Med       Date:  2015-10-23       Impact factor: 5.310

Review 6.  New insights into ANGPLT3 in controlling lipoprotein metabolism and risk of cardiovascular diseases.

Authors:  Xin Su; Dao-Quan Peng
Journal:  Lipids Health Dis       Date:  2018-01-15       Impact factor: 3.876

7.  Maternal GALNT2 Variations Affect Blood Pressure, Atherogenic Index, and Fetal Growth, Depending on BMI in Gestational Diabetes Mellitus.

Authors:  Linbo Guan; Ping Fan; Xinghui Liu; Mi Zhou; Yujie Wu; Rui Liu; Yu Liu; Huai Bai
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-29       Impact factor: 5.555

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.